China nuclear power IPO takes first steps

China's largest pure nuclear power play attracts high demand from both retail and institutional investors.

CGN Power’s asset injection from its parent has not been taken well by investors. They have questions about how to value the assets and worry about the impact on leverage.

Even if Hong Kong's social landscape remains fractured, biotech firms continue to be lured to the HKEX, with Ascentage Pharma the latest to float.

With its online ticketing business Maoyan Entertainment looking to raise $345 million from its IPO, Tencent is set to go head-to-head against Alibaba on the Hong Kong stock exchange.

In the second instalment of our China Awards series, FinanceAsia reveals the thinking behind our awards for Best Deals and Borrowers.

Pricing of Chinese paediatric hospital operator's deal indicates 2017 could again see sheer weight of onshore demand keep IPO valuations above levels offshore investors believe the fundamentals warrant.